OTHER

Khosla Ventures Makes Significant Investment in Even Healthcare to Transform Hospital Economics in India

Even Healthcare has successfully raised $50 million in a funding round led by Khosla Ventures, with the aim of transforming revenue generation methods for hospitals and enhancing doctor incentives in India, the most populated country in the world.

The Series B funding, which is completely equity-based, also drew investment from Alpha Wave, elevating Even’s valuation to $300 million—effectively tripling its value within just 18 months, as reported by the company. With this latest funding, Even has amassed over $120 million in total investments.

In India, hospitals often boost profits through unnecessary tests, procedures, or by unnecessarily prolonging patient discharges, regardless of actual medical necessity. Even’s goal is to realign healthcare priorities towards patient welfare, aiming to reduce unnecessary treatments that drive up medical expenses.

This strategy has consistently resonated with Khosla Ventures, which has been a supporter of Even since its initial seed funding in 2021. The Silicon Valley venture capital firm is increasing its investment as Even starts to establish and manage its own hospitals, allowing for better control over patient care and associated costs.

Vinod Khosla, the founder of Khosla Ventures, stated that Even’s approach addresses more than just isolated issues within a fragmented healthcare system by combining finance, technology, and care delivery. He highlighted the necessity of rewarding positive health outcomes rather than merely the quantity of healthcare services provided.

“The clinical and economic results we’ve observed so far reinforce our belief that this could be a revolutionary healthcare model for India and beyond,” Khosla remarked.

Initially, Even collaborated with hospitals to deliver care for its members. However, co-founder Mayank Banerjee disclosed in an interview that the startup reevaluated this model upon realizing that many patients were subjected to unnecessary tests or procedures.

“We found that patients were receiving inadequate care while insurers faced considerable financial burdens. Therefore, we opted to establish our own hospitals,” Banerjee explained to TechCrunch.

To date, Even has opened two hospitals in Bengaluru, both attaining operational profitability—excluding depreciation—within their first year, as Banerjee noted. The startup plans to launch five additional hospitals in the city within the next six months, supported by this recent capital influx.

Banerjee mentioned that Even leases its hospital facilities through long-term contracts and allocates resources toward procuring equipment and medical devices.

Unlike conventional hospitals that provide financial incentives for doctors to prescribe more procedures, Even offers physicians fixed salaries that are not tied to the number of tests or surgeries performed. Banerjee highlighted that doctors can also receive bonuses based on patient-reported clinical outcomes.

This principle applies to hospital management as well; their compensation is not linked to the number of procedures conducted, Banerjee explained to TechCrunch. Managers are compensated with salaries along with collective incentives, while marketing teams concentrate on patient acquisition rather than revenue per patient. Moreover, all staff, including doctors, hold equity in Even, fostering a shared interest in the startup’s long-term success rather than inflating medical costs.

A significant part of Even’s revenue comes from patients directly paying for their treatments, according to Banerjee. The startup also generates income through partnerships with insurers and is developing a model that motivates Even to effectively prevent hospitalizations, rather than simply managing treatments.

Banerjee informed TechCrunch that Even monitors patient recovery after treatment using established medical scoring systems. For instance, it applies the Oxford Knee Score to assess pain and mobility following knee replacement surgeries. The results are made available on its website alongside statistics from other healthcare systems for benchmarking.

Even reports an unplanned readmission rate of below 1%, in contrast to the industry average of 8% to 15%. The startup also asserts that patients spend 40% less time in the hospital and that its practices have saved insurers over ₹500 million (roughly $5.27 million).

Jai Sajnani, a partner at Khosla Ventures, commented to TechCrunch that Even’s early results significantly influenced the firm’s choice to lead this funding round. “We are excited to assist the Even team in providing quality healthcare to families in Bengaluru and throughout India,” he expressed.

Despite these accomplishments, Even is currently operating at a loss. The startup reported a net loss of ₹902 million (about $9.50 million) for the fiscal year 2025, which is an increase of nearly 25% compared to the previous year, with revenues totaling ₹272 million (around $2.86 million), according to regulatory filings.

In August, Even also laid off approximately 350 employees, as reported by the Indian startup news outlet Entrackr. Banerjee addressed the restructuring, calling it a tough decision, and noted that those impacted received severance packages, extended health benefits, and expedited equity vesting.

Currently, Even employs about 650 individuals, including roughly 300 full-time doctors. The startup has around 250,000 members and has recorded over 750,000 patient interactions since its inception in 2021, which includes consultations, diagnostic procedures, and surgeries, as stated by Banerjee.

Banerjee mentioned to TechCrunch that Even could achieve profitability within months if it halted its growth; however, the startup has decided to prioritize expansion. He did not provide a timeline for when Even anticipates reaching profitability.

“At this moment, our focus is on expansion and catering to a wider patient demographic,” Banerjee confirmed.

When you make purchases through links in our articles, we may earn a small commission. This does not affect our editorial independence.